Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Arch Biopartners Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(9)
•••
Post by Riverfolkon Nov 09, 2021 4:06pm
107 Views
Post# 34106617

$3.65 - Extremely Undervalued in Comparison to peers

$3.65 - Extremely Undervalued in Comparison to peers

The recent realization by the market has made the Arch chart look incredible, but lets no forget that we are extremely undervalued compared to our peer 


Current Market cap 182 mil US

We are waiting on Phase II Human Clinical Trial Data by a third party for a 20 billion a year unmet market.


BLU is currently 695 mil market cap for Chronic Cough (Phase 2)

VXRT is currently 888 mil market cap  US Oral Vaccines

SAVA is 2 billion US market cap for Blood Cancer (Phase 2)

CYDY is 1.1  billion US market cap for Antibodies

TRIL was 2.2 billion buyout (Phase 2)

As we wait on data, there is no reason why we are not at a 695 million market cap of $11.20. We have fully patented new mechanism of action with a drug library. IMHO we will be 10x this current price if data deems it worthy.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities